SIP Stock Pick For New Year 2025: Anil Singhvi recommends buying this largecap pharma stock on 10% dip
Largecap SIP Stock in New Year 2025: As leading indices, BSE Sensex and Nifty 50, are in green on the first 2 days of the Year 2025, market guru and Zee Business managing editor, Anil Singhvi, has recommended buying Mankind Pharma on a dip.
Largecap SIP Stock in New Year 2025: Benchmark Indices, BSE Sensex and Nifty 50, started the session today (Thursday, January 2, 2025) on a rousing note after ending the first session of the year in green. At the time of writing the article, the BSE Sensex was up by 707.12, at 79,214.53, while the Nifty 50 index was trading higher by 213 points, at 23,956 points. As the indices seem to be on the recovery path, Zee Business managing editor Anil Singhvi has picked largecap pharma giant Mankind Pharma for long-term investment and has recommended investors buy it in a dip. Check out what he says about the pharma company.
Photos: Unsplash/Pixabay
Anil Singhvi on Mankind Pharma
What makes Mankind Pharma special
Anil Singhvi says that Mankind Pharma is a fast-growing Indian pharma company.
Anil Singhvi on Mankind Pharma market portfolio
He says it has a diversified brand portfolio with a strong market share.
Anil Singhvi on Mankind Pharma's brand launch
The Zee Business managing editor says that Mankind Pharma has launched 10 new brands in the last 4 years.
Anil Singhvi on Mankind Pharma's key brands
He says the pharma firm has a strong healthcare portfolio with products such as Mainforce and Preganews.
He says Acne Star and Unwanted72 add strength to its healthcare portfolio.
Anil Singhvi on Mankind Pharma's growth areas
Singhvi says that the pharma giant's growth is expected from its expansion in the chronic diseases segment.
It has made strategic acquisitions in businesses with high entry barriers, says Singhvi.
Anil Singhvi's past target on Mankind Pharma
The market guru has been bullish on the largecap pharma stock.
He had recommended buying the stock at Rs 2,132 on March 22, 2024, as part of his Wealth Creation PICK series.
Mankind Pharma investment horizon
On January 2, 2024, Singhvi picked Mankind Pharma for an investment horizon of 1-2 years.
When should one invest in Mankind Pharma?
Singhvi says that investors should do SIP on every 10 per cent fall in the largecap stock price.
Mankind Pharma share price
The stock of the company with a market capitalisation of Rs 1,20,259.13 crore closed trading on BSE January 1 at Rs 2,887.45.
Mankind Pharma 1-year share price history compared to Nifty 50
The stock has risen by 38.19 per cent in the last 1 year.
The benchmark index, Nifty 50, has risen by 11.05 per cent in the same year.